What is Targan?
Targan operates at the intersection of biotechnology and industrial agriculture, providing a sophisticated array of state-of-the-art technologies designed to optimize production yields. By eliminating the reliance on antibiotics and chemical additives, the company addresses the growing global demand for sustainable and humane food production systems. Its market position is defined by a commitment to operational efficiency, positioning it as a critical infrastructure provider for large-scale producers seeking to modernize their supply chains while adhering to stringent health and safety benchmarks.
How much funding has Targan raised?
Targan has raised a total of $100M across 1 funding round:
Private Equity
$100M
Private Equity (2026): $100M with participation from Symbiotic Capital
Key Investors in Targan
Symbiotic Capital
Symbiotic Capital specializes in providing healthcare credit solutions aimed at supporting the scientific community, focusing on facilitating access to financial resources for organizations within the healthcare and life sciences sectors.
What's next for Targan?
With this latest round of financing, Targan is well-positioned to scale its proprietary technology suite across broader international markets. The strategic roadmap likely involves accelerating research and development cycles to further refine its yield-maximization tools and expanding its commercial footprint to meet the needs of enterprise-level agricultural operations. As the industry shifts toward chemical-free production, Targan's ability to maintain high-output efficiency without compromising animal welfare or product quality will be the primary driver of its long-term valuation and competitive advantage in the ag-tech sector.
See full Targan company page
